Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiwan To Kick Off Public/Private Biotech Funding Venture

This article was originally published in PharmAsia News

Executive Summary

Taiwan plans to create a public-private biotechnology venture capital firm in an effort to build the industry as one of six the government has emphasized. The bioventure would receive 40 percent of its funds from the government, the rest to come from the private sector. The nation's Executive Yuan Council is earmarking up to $296 million in seed money for the first phase of the initiative. The five other industries, including pharmaceutical and healthcare industries, are to receive their own joint venture funding programs in the future. (Click here for more - a subscription may be required

You may also be interested in...



Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs

Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.

Veklury Takes Gilead Earnings On Wild Ride

The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.

Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations

The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.

UsernamePublicRestriction

Register

LL1127674

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel